The influence of two functional genetic variants of GRK5 on tau phosphorylation and their association with Alzheimer’s disease risk

Yuan Zhang1,2,*, Jianghao Zhao1,*, Mingkang Yin1,*, Yujie Cai1, Shengyuan Liu3, Yan Wang4, Xingliang Zhang5, Hao Cao6, Ting Chen7, Pengru Huang1, Hui Mai1, Zhou Liu1, Hua Tao1, Bin Zhao1 and Lili Cui1

1Guangdong Key Laboratory of Age-related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
2Institute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, China
3Department of Chronic Disease, Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, China
4Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi’an Jiaotong University, Xi’an, China
5Department of Pediatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
6Departments of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
7Clinical Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
*Authors contributed equally to this work

Correspondence to: Bin Zhao, email: binzhaoe@163.com
Lili Cui, email: cuilili@gdmu.edu.cn

Keywords: GRK5, polymorphisms, p-tau, β-amyloid, Alzheimer’s disease

Received: April 19, 2017  Accepted: July 23, 2017  Published: August 16, 2017

Copyright: Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Our work explores the relationship between G protein-coupled receptor kinase-5 (GRK5) single nucleotide polymorphisms and Alzheimer’s disease risk. We confirmed that GRK5 translocates from the cellular membrane to the cytosol in the hippocampus of Alzheimer’s disease mice and that GRK5 deficiency promotes tau hyperphosphorylation, a hallmark of Alzheimer’s disease pathology. Our results indicate that one functional variant, or mutant, of GRK5 (GRK5-Gln41Leu) decreased GRK5 translocation from the membrane to the cytoplasm and reduced tau hyperphosphorylation, whereas, another GRK5 mutant (GRK5-Arg304His) increased GRK5 translocation to the cytoplasm and promoted tau hyperphosphorylation. In addition, case-control studies revealed that GRK5-Gln41Leu is associated with a lower risk of late-onset Alzheimer’s disease. Our findings suggest that the GRK5-Gln41Leu mutant may resist tau hyperphosphorylation by promoting GRK5 membrane stability and, in effect, may contribute to lower Alzheimer’s disease risk.

INTRODUCTION

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder clinically characterized by the progressive loss of memory and other neurological functions. Influenced by genetic and environmental factors, the mechanisms leading to AD occurrence are complex. Mutations in three genes, amyloid precursor (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2), play extremely important roles in Aβ42 metabolism, and these mutations have been identified as risk factors for Early Onset Alzheimer Disease (EOAD) [1, 2]. The ε4 allele of apolipoprotein E (ApoE) has been identified as an important susceptibility gene for Late Onset Alzheimer Disease (LOAD) [3, 4], while many other genes also associated with LOAD susceptibility to varying degrees.
G protein-coupled receptor kinase-5 (GRK5) is one of the seven GRK family members whose primary function is to desensitize G protein-coupled receptors (GPCRs), which is essential for the desensitization and internalization of M2/M4 receptors [5]. Reduced levels of membrane (functional) GRK5 increased soluble β-amyloid in vitro, and decreased GRK5 membrane localization occurs in vivo as well as in an AD transgenic model and postmortem human AD brain samples [6, 7]. GRK5 dysfunction mediates the deleterious cycle between cholinergic hypofunction and tau hyperphosphorylation, leading to increased β-amyloid deposition in the hippocampus [8, 9]. Moreover, it has been reported that the proteolytic processing of APP is regulated by a variety of GPCRs, including cholinergic, serotoninergic, and glutamatergic receptors [9], suggesting that GRK5 may also play a role in GPCRs mediated APP metabolic pathway.

Recent studies have characterized the significant genetic variants of GRK5 that modify the risk of disease such as heart failure, hypertension, diabetes and Parkinson’s disease [10-12]. It has also been reported that functional genetic polymorphisms of GRK5 could influence β-adrenergic signaling [13, 14]. We propose that the functional genetic polymorphisms in the genes coding for GRK5 may be important pharmacogenetic targets that offer opportunities for novel personalized medicine approaches. To the best of our knowledge, the association of GRK5 polymorphisms with pathogenesis and AD risk has not yet been explored. In the present study, we screened the GRK5 gene for the two main genetic variants in coding region of GRK5 (rs2230345 and rs2230349), exploring the possible influence of the SNPs on GRK5 function and AD risk.

RESULTS

GRK5 distribution from membrane to cytosol in the hippocampus of aged APP/PS1 transgenic mice

The physical location of GRKs, which is determined at least in part by a counterbalance between their binding factors in the membrane and cytosol, is a critical factor regulating interaction, including binding, between GRKs and G-protein-coupled receptors. Thus, we first examined the hippocampi of APP/PS1 transgenic mice of different ages to determine whether the subcellular distribution of GRK5 was altered. As shown in Figure 1A, the GRK5 expression levels in the membrane fraction were significantly decreased in 9-month-old transgenic mice and even more in 14-month-old mice compared with 3-month-old mice and also compare to the WT mice of same age (P<0.05). No significant change was observed in the subcellular fractions between different aged groups of WT mice (Figure 1A).

GRK5 deficiency induced tau hyperphosphorylation

It has been reported that GRK5 deficiency triggers tau hyperphosphorylation and, thus, causes axonal swelling and functional damage of neurons. To further confirm the effect
of GRK5 on tau hyperphosphorylation, we also analyzed p396-tau levels in the hippocampus of APP/PS1 transgenic mice and GRK5KO mice at a range of ages. The level of p-tau in the hippocampus of GRK5KO mice was elevated at 4-5 months aged, which was not significantly different than the APP/PS1 transgenic mice in both young (4-5 months) and older age (14-15 months) groups (Figure 1B). This confirmed that GRK5 deficiency exaggerates tau hyperphosphorylation in the hippocampus in vivo in the younger age group. The distribution change of GRK5 also occurs relatively early in the pathologic process of AD, and GRK5 deficiency tends to be more susceptible to the effect of Aβ deposition, causing brain dysfunction.

Selection of GRK5 gene SNPs

The selection of GRK5 SNPs was based on information from databases, such as dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), SNPinfo (http://snpinfo.niehs.nih.gov/) and SNPexus (http://www.snp-nexus.org/). Two polymorphisms in GRK5 exons with an allele frequency greater than 1% in the Chinese Han ethnic group, GRK5-Gln41Leu (rs2230345, A/T) and GRK5-Arg304His (rs2230349, G/A) variants, were finally selected for further study (Figure 2A). Tertiary structures of WT and two mutant GRK5 proteins encoding the SNPs rs2230345 or rs2230349 were then simulated using comparative modeling as shown in Figure 2B. The glutamine (Gln) residue at position 41 in the native protein was replaced by leucine (Leu), and the arginine (Arg) residue at position 304 was replaced by histidine (His). The protein structures showed that Gln41 was located in the N-terminal calmodulin/PIP2 binding domain, which is important for GRK5 binding to membranes. The substitution of the polar amino acid Gln41 for the non-polar amino acid Leu41 may enhance GRK5 stability on the membrane, thereby strengthening receptor phosphorylation activity. Arg304 was located in the C-domain, which may interact with the kinase domain, and the substitution of Arg-to-His at amino acid 304 of GRK5 may disrupt the catalytic functions of the kinase domain.

Influence of GRK5-Gln41Leu and GRK5-Arg304His on GRK5 translocation and tau hyperphosphorylation

To explore the possible influence of the Gln41Leu or Arg304His mutations on GRK5 function and tau hyperphosphorylation, the mutant vectors for GRK5-Gln41Leu (rs2230345) and GRK5-Arg304His (rs2230349) were constructed, respectively (Figure 2C). As shown in Figure 2D, SH-SY5Y cells were either transfected with the WT vector or with Gln41Leu or Arg304His mutant vectors with a high efficiency. The expression levels of total GRK5 were not significantly different between the GRK5-Gln41Leu or GRK5-Arg304His groups and the WT group. As shown in Figure 3A and 3B, the level of GRK5 on the membrane in the GRK5-Gln41Leu group was slightly more than the GRK5-Arg304His group, while there was no significant difference compared with the WT group. In the GRK5-Arg304His mutant group, the GRK5 level in the cytoplasm was significantly higher than both the WT and the GRK5-Gln41Leu groups. In addition, western blot and ELISA analyses showed that the level of p-tau was significantly increased in the Arg304His group, and the level of tau phosphorylation in the Gln41Leu group was not significantly different than the WT group (Figure 3C-3E). These results suggest that the GRK5-Arg304His mutant may disrupt GRK5 function, leading to increased expression of p-tau in SH-SY5Y cells.

GRK5-Gln41Leu rescued tau hyperphosphorylation with low threshold Aβ42 stimulation

To determine the impact of β-amyloid on GRK5 function, we exposed SH-SY5Y cells to 1 μM or 5 μM Aβ42 for 24h and separated the cell lysates into membrane and cytosolic fractions for subsequent Western blotting (Figure 4A). Distribution of GRK5 occurred at the 1 μM threshold of Aβ42 oligomer stimulation but not at the 5 μM threshold, indicating a possible dose-dependent mechanism. Therefore, the 1 μM Aβ oligomer dose was chosen for use in subsequent experiments.

We found that after low threshold Aβ42 stimulation, the distribution of GRK5 in the Gln41Leu group was clearly different than the WT group. However, there was no significant difference between the WT group and the GRK5-Gln41Leu with Aβ42 stimulation group. Whereas, GRK5 levels in the GRK5-Arg304His with Aβ42 stimulation group were significantly decreased on the membrane and increased in the cytoplasm (Figure 4B). Furthermore, both the WT and GRK5-Arg304His groups showed increased p-tau after Aβ42 stimulation, while the GRK5-Gln41Leu groups showed lower p-tau than WT groups (Figure 4C). Taken together, the results suggest that the GRK5-Gln41Leu mutant may prevent GRK5 translocation from the membrane to the cytosol as well as subsequent tau phosphorylation under Aβ42 stimulation. In contrast, the GRK5-Arg304His mutant was more sensitive to Aβ42, increasing GRK5 in the cytosol and p-tau expression.

Analysis of AD clinical parameters

Based upon the above functional assay, we hypothesized that the two SNPs influence GRK5 function and might contribute to AD susceptibility. Thus, we further explored the relationship between the two GRK5 polymorphisms and the risk of AD in a case-control study. A total of 292 patients diagnosed with AD and 300 unrelated gender- and age-matched controls were analyzed.
in our study. The demographic and clinical characteristics of the study subjects are summarized in Table 1. The mean age was 73.6 years for the AD patients and 74.1 years for the control subjects; the gender (male-to-female) ratio was 1:1.41 in the case group and 1:1.31 in the control group. The distributions of age and gender did not significantly differ between the AD patients and controls (P=0.6201 and 0.4479, respectively). The MMSE score was significantly lower in AD patients than in controls (P<0.001). Moreover, as expected, the ApoEε4 allele frequencies were significantly elevated in AD patients versus those in controls (P<0.0001). All of the patient samples were genotyped for the rs2230345 and rs2230349 SNPs, and the association between the genotype and the risk of AD was analyzed using the Chi-squared test.

### Genetic association of AD with SNPs of GRK5 rs2230345 and rs2230349

All of the genotype distributions followed the Hardy–Weinberg equilibrium in the AD cases and controls. The allele and genotype frequencies of the GRK5 polymorphisms in the entire study population are shown in Table 2. Neither the genotype nor allele frequencies for the rs2230345 SNP showed significant differences between the AD cases and controls (genotypes P=0.223 and alleles P=0.225). However, in the LOAD subgroup, the T allele of rs2230345 SNP was associated with a lower risk of LOAD compare to the control groups (P=0.0472) (Table 2), while no differences were observed for the genotype of rs2230345 SNP (P=0.123). Moreover, the

![Figure 2: Selection of GRK5 gene SNPs.](image)

**Figure 2: Selection of GRK5 gene SNPs.** (A) Minor allelic frequency of represented SNPs that locate in Homo sapiens GRK5 exons are depicted in green symbols and two sites are eye-catching for their larruping occurrence rate in Chinese Han ethnic group. (B) Protein modeling based on rs2230345 (Q41L) and rs2230349 (R304H) GRK5 SNPs. Structural model of the (a) native protein (Q41/R304) and (b) mutant protein (L41/H304) of GRK5. (c)-(e) Superimposed model of native and mutant proteins of GRK5-Q41L. (f)-(h) Superimposed model of native and mutant proteins of GRK5-R304H. Domain organization and important functional regions of GRK5 are represented with different colors, with the C-tail of the kinase domain in indigo blue and the CaM/PIP2-binding sites in cyan. The mutation sites are indicated by red circles. (C) Schematic and sequence diagram of two GRK5 mutant vectors, Gln41Leu (rs2230345) and Arg304His (rs2230349). (D) SH-SY5Y cells were transfected with Gln41Leu, Arg304His vectors or the empty vector.
rs2230345 SNP showed no significant differences for genotype or allele frequencies in the EOAD subgroup (genotype P=0.962, allele P=0.977). With regard to the other SNP, neither the rs2230349 genotype nor the allele showed significant differences between the AD cases and the controls (genotype P=0.142, allele P=0.130) (Table 2), and no significant difference was observed in the age of disease onset subgroups (LOAD: genotypes P=0.618, alleles P=0.411, EOAD: genotypes P=0.139, alleles P=0.127) (Table 2).

The individual genotype data for the two GRK5 SNPs were also analyzed for the predicted haplotypes and are shown in Table 3. For the two predicted haplotypes of the GRK5 gene (for rs2230345 and rs2230349), T-G was significantly associated with AD risk versus controls (P=0.013).

**DISCUSSION**

Mutations and SNPs of the GRK family may alter GRK function and are associated with several cardiocerebral vascular diseases, such as cardiac failure, ischemia and coronary artery disease [15-17]. GRK5 is either localized at the membrane or is recruited into the membrane to execute its primary function on G-protein-coupled receptor desensitization [18, 19]. Recent studies suggest that GRK5 deficiency may impair the desensitization of presynaptic muscarinic 2 (M2) autoreceptors [5, 20]. GRK5 deficiency may also be associated with tau hyperphosphorylation, a hallmark of AD, and play a significant role in its pathogenesis [5, 21, 22]. Our results confirm that GRK5 levels significantly increase in the membrane fraction but decrease in the cytosolic fraction of older APPsw mice. Furthermore, p396-tau expression in the hippocampus of GRK5KO mice significantly increased versus APP/PS1 transgenic mice. These results combined with previous reports further confirm that functional GRK5 deficiency causes tau hyperphosphorylation and may contribute to the development of AD [23, 24].

To assess which SNPs may affect GRK5 functionality and may be associated with AD risk, we performed a comprehensive screen of the coding region of the GRK5 gene for polymorphisms with minor allele frequency (MAF) > 0.01%. Finally, two non-synonymous polymorphisms in AD with potential functional impact were chosen to evaluate their possible effects on GRK5 function and their association with AD: cDNA nucleotide position 122 A/T changes glutamine (Gln) to leucine (Leu) at amino acid 41 (rs2230345) and nucleotide 840 G/A changes arginine (Arg) to histidine (His) at amino acid 304 (rs2230349) [25, 26].

We explored the molecular mechanism of the rs2230345 on the GRK5 function by the crystal structure.

---

**Figure 3: Influence of GRK5-Gln41Leu and Arg304His on GRK5 translocation and tau hyperphosphorylation.** (A) Western blotting analysis of GRK5 levels in GRK5 mutant cells and control cells. (B) Quantitative analysis of GRK5 expression in GRK5 mutant cells and control cells. (C) Western blotting analysis of p-tau expression in GRK5 mutant cells and control cells. (D) Quantitative analysis of GRK5 mutant cells and control cells on p-tau expression. *p<0.05, compared with WT. (E) ELISA analysis of p-tau level in GRK5 mutant cells and control cells. *p<0.05, compared with WT.
Analysis of the protein structures demonstrated that Gln41 was located in the N-terminal calmodulin/PIP2 binding domain, which is important for GRK5 binding to the membrane [27, 28]. Since leucine likely binds better to the membrane than glutamine, Gln41Leu mutation has the more ability to desensitize GPCRs [7]. CaM binding to N-terminal regions of GRK5, which largely overlap with the membrane-binding determinants, would block GRK5 association with membranes, thereby attenuating GPCR phosphorylation and leading to desensitization of the receptors [29-32]. The substitution of the polar amino acid Gln41 with the non-polar amino acid Leu41 might be responsible for promoting the stability of GRK5 on the membrane, thereby strengthening receptor phosphorylation activity, which is consistent with reports involving heart failure [18, 29]. As our results indicated, there were no obvious changes in the distribution of GRK5 in the GRK5-Gln41Leu group. However, the Gln41Leu mutation did inhibit GRK5 translocation from membrane to cytoplasm and protect tau hyperphosphorylation in SH-SY5Y cells after Aβ42 stimulation. As might be expected for a polymorphism within a putative regulatory domain, Leu41 was markedly

Table 1: Demographic data and clinical features of patients with AD Patients and healthy controls.

| Characteristics     | Controls (n=300) | AD cases (n=292) | P value |
|---------------------|-----------------|-----------------|---------|
| Age (years)         | 73.6±8.29       | 74.1±7.72       | 0.4479  |
| Gender (M/F)        | 130/170         | 121/171         | 0.6201  |
| MMSE scores         | 28.7±0.82       | 18.4±6.22       | <0.001  |
| ApoEε4(+)           | 54              | 121             | <0.0001 |

Figure 4: GRK5-Gln41Leu variant protects against low threshold Aβ42 stimulation. (A) Western blotting analysis of GRK5 expression in membrane and cytosolic fractions of SH-SY5Y cells exposed to 1 μM or 5 μM Aβ42 for 24 h. *p<0.05, compared with NC. (B) Western blotting analysis of GRK5 expression in cells with GRK5-Gln41Leu or Arg304His mutations exposed to 1 μM Aβ42. *p<0.05, compared with WT; *p<0.05, compared with the group of WT stimulated with Aβ42. (C) Western blotting analysis of p-tau in cells with GRK5-Gln41Leu or Arg304His mutations exposed to 1 μM Aβ42. *p<0.05, compared with the group of WT stimulated with Aβ42. (D) ELISA analysis of p-tau in cells with GRK5-Gln41Leu or Arg304His mutations exposed to 1 μM Aβ42. *p<0.05, compared with WT.
more effective than Gln41 in promoting the stability of GRK5 on the membrane and inhibiting tau hyperphosphorylation when cells were stimulated with Aβ42. Consistent with the findings obtained from the functional assay and case-control study, the missense variation rs2230345 in the GRK5 gene is associated with LOAD resistance by its T allele distribution. The GRK5-Gln41Leu (rs2230345) mutant could influence the translocation of GRK5 and may protect the tau hyperphosphorylation in the pathology of AD, which ultimately may contribute to LOAD susceptibility.

Taken together, the results of our study indicate that GRK5-Gln41Leu might serve as a potential marker for LOAD resistance.

In contrast, the Arg304His mutation affects the function of the GRK5 catalytic domain rather than the membrane-binding function and was more sensitive to Aβ42, leading to increased levels of GRK5 in the cytosol and the expression of p-tau [28]. Arg304 was located in the C-domain, which might interact with the kinase domain. Studies have shown that when arginine 304 was exchanged for cysteine the kinase appeared to be evenly distributed between the cytosol and the plasma membrane. The substitution of Arg-to-His at amino acid 304 of GRK5 might disrupt the catalytic functions of the kinase domain, enhancing the toxicity of Aβ42.

GRK5 encodes a member of the guanine nucleotide-binding protein (G protein)-coupled receptor kinase

Table 2: Frequencies of GRK5 genotypes and alleles among LOAD/EOAD subgroups in cases and controls

| Genotypes n (%) | Alleles n (%) | P-value | OR (95% CI) |
|----------------|--------------|---------|-------------|
| rs2230345      |              |         |             |
| AD             | 289 (98.97%) | 3 (1.07%) | 0 (0%) | 0.223 | 581(99.49%) | 3(0.51%) | 0.225 | 2.617(0.691-9.917) |
| Control        | 292 (97.33%) | 8 (2.67%) | 0 (0%) | 0.232 | 592(98.67%) | 8(1.33%) |
| LOAD (>65 years) |           |          |         |       |         |         |         |         |
| AD (189)       | 189         | 0        | 0       | 0.123 | 378     | 0       | 0.0472 | 8.906 (0.478-166.1) |
| Control (193)  | 189         | 4        | 0       | 0.062 | 382     | 4       |
| EOAD (<65 years) |         |          |         |       |         |         |         |         |
| AD (103)       | 100         | 3        | 0       | 0.962 | 206     | 3       | 0.977 | 0.976 (0.195-4.895) |
| Control (107)  | 104         | 3        | 0       | 0.962 | 211     | 3       |

rs2230349

| Genotypes n (%) | Alleles n (%) | P-value | OR (95% CI) |
|----------------|--------------|---------|-------------|
| rs2230349      |              |         |             |
| AD             | 135 (46.23%) | 123 (42.12%) | 34(11.64%) | 0.142 | 393 (67.3%) | 191 (32.7%) | 0.130 | 0.820 (0.640-1.051) |
| Control        | 150 (50.00%) | 129 (43%) | 21 (7%) | 0.618 | 429 (71.5%) | 171 (28.5%) |
| LOAD (>65 years) |           |          |         |       |         |         |         |         |
| AD (189)       | 89          | 80       | 20      | 0.618 | 258     | 120     | 0.411 | 0.8788 (0.645-1.197) |
| Control (193)  | 96          | 82       | 15      | 0.618 | 274     | 112     |
| EOAD (<65 years) |         |          |         |       |         |         |         |         |
| AD (103)       | 46          | 43       | 14      | 0.139 | 135     | 71      | 0.127 | 0.7238 (0.478-1.096) |
| Control (107)  | 54          | 47       | 6       | 0.139 | 155     | 59      |

Table 3: The haplotype frequencies of GRK-5 polymorphisms in Chinese Han population

| Haplotype | Frequency | Case Frequency | Control Frequency | P Value |
|-----------|-----------|----------------|-------------------|---------|
| A-G       | 0.682     | 0.706          | 0.660             | 0.606   |
| A-A       | 0.300     | 0.291          | 0.307             | 0.761   |
| T-G       | 0.018     | 0.003          | 0.033             | 0.013   |
subfamily of the Ser/Thr protein kinase family and is located in chromosome band 10q26.11 [32-35]. GRK5 dysfunction affects muscarinic signaling and promotes tau hyperphosphorylation through PKC-mediated activation of GSK3β signaling pathways in vivo, which might be a potential pathogenic link in AD [23]. GRK5 deficiency appears to connect cholinergic hypofunctioning and Aβ42 accumulation in a self-promoting loop cycle that accelerates both activities [9, 36]. As described, GRK5 deficiency has emerged to become a critical player in AD pathogenesis that might result from excess Aβ42 accumulation and that can conversely enhance Aβ42 toxicity, leading to cholinergic dysfunction and tau hyperphosphorylation.

Based on previous studies, we propose a functional mapping for evaluating the impact of the rs2230345 and rs2230349 polymorphisms on GRK5 function and tau phosphorylation. As shown in Figure 5, GRK5-Gln41Leu performed a gain-of-function by enhancing its membrane-binding properties, which serves as a resistance in AD patients. However, the GRK5-Arg304His mutant might function as GRK5 deficiency in vivo, which was more sensible to Aβ. In this vicious cycle, Aβ42 and cholinergic dysfunction each serve as the causes and consequences, whereas GRK5 deficiency amplifies these effects [37]. In addition, it has been reported that the GRK5 dysfunction constitutes a crucial regulatory step for tau hyperphosphorylation by activating GSK3β signaling pathways, another known risk factor for AD [23, 38].

Some potential limitations of our study should be addressed. First, we found that two SNPs affected GRK5 function, but only rs2230345 showed a significant correlation in the case-control study. We speculate that the results of the case-control analysis in AD remain preliminary due to the small number of subjects, and further investigation of the GRK5 polymorphisms with a larger and more ethnically diverse population of AD patients is warranted. In addition, these results are based primarily on in vitro cell culture models. We will use transgenic animal models for in vivo studies aimed to explore the association between the two polymorphisms and the pathology process of AD.

In conclusion, our results suggest that the two SNPs, rs2230345 and rs2230349, may contribute to AD susceptibility through their influence on GRK5 function and tau hyperphosphorylation. Therefore, these functional genetic variants of GRK5 merit consideration and further investigation as therapeutic targets for the treatment of AD, offering opportunities for novel personalized medicine approaches.

Figure 5: The functional mapping for evaluating the impact of the rs2230345 (GRK5-Gln41Leu) and rs2230349 (GRK5-Arg304His) polymorphisms on GRK5 function and tau phosphorylation.
MATERIALS AND METHODS

Animal preparation

Three murine models were used in this study, GRK5 knockout (GRK5KO) mice (GRK5+/−), APP/PS1 double transgenic (AD) mice (APP+/−/PS1+/−) and wild-type (WT) C57BL/6 mice (GRK5+/+APP+/+PS1+/+). AD and WT mice were acquired from the Institute of Laboratory Animal Center of Guangdong Province (Guangdong, China). GRK5KO mice were acquired from Cyagen Biosciences (Guangzhou) Inc. (Guangzhou, China). The GRK5 gene was targeted with the Cas9 protein using a guide-miRNA in zygote cells. The targeting structure introduced two guide-miRNA matching sites in the transcript flanking exons 2 and 3 as well as with a marker gene cassette near the matching sites. Microinjection of homologous embryonic stem cell (ESC) clones with Cas9-recombinase resulted in the loss of the sequences between the two matching guide-miRNA sites, leading to deletion of the marker genes and exons 2 and 3 of the GRK5 gene. When GRK5 mutant ESCs divided into blastocysts, embryo transplantation was performed in C57BL/6 mice. Three genotypes were produced from these mice: GRK5 mutant heterozygote mice (GRK5+/−), GRK5 mutant homozygous mice (GRK5−/−) and wild-type GRK5 mice. PCR amplification and DNA genotyping were used to identify knockouts. A homozygous GRK5KO strain (GRK5−/−) was generated by cross breeding GRK5−/− mice together for at least 6 generations. All mice were housed in a specific-pathogen-free (SPF) room with normal daily periodicity and were provided with sterile rodent chow and water at regular intervals.

The use of these animals was approved by the Guangdong Medical University Laboratory Animal Center Committee, and the experiments were performed according to the permitted agreements. Experimental animals were conventionally raised a week after purchase with a room temperature maintained at 22-25°C and 10-50% relative humidity with a 12 h light/dark cycle. The animals were allowed free access to food and water.

Preparation of human β-Amyloid 1-42 (Aβ42) oligomers

Human Aβ42 was purchased from ChinaPeptides Co., Ltd. (Shanghai, China). Aβ42 was dissolved at a final concentration of 1 mg/ml with the addition of hexafluoroisopropanol (HFIP) followed by a 10 min ultrasound bath, vacuum drying and redissolution. Eventually, an Aβ42 solution (Aβ42 monomers) was dissolved in dimethyl sulfoxide (DMSO) at a final concentration of 2 mg/ml. The fresh Aβ42 solutions were used for experiments immediately, and the remaining solution was stored at -80°C.

DNA isolation and genotyping for the SNPs

Peripheral blood samples were collected, and genomic DNA was isolated using the blood Genomic DNA Extraction Kit (Tiangen, China). The genomic DNA was genotyped using the ABI PRISM SNapShot method (Applied Biosystems, Foster, CA, USA). Two target fragments were captured by amplification with two pairs of primers that included rs2230345-F: 5’-AGGCTCACGCGGATCTTTT-3’, rs2230345-R: 5’-CGGCTACACCCTTGGCTTAAT-3’, rs2230349-F: 5’-TCAACCTGGGCTATGGCCTAGCA-3’ and rs2230349-R: 5’-CTTGGAAATCCTTGGTGCCCTCC-3’. Briefly, a 10 μl final volume of PCR reaction mixtures was added to 5 μl SNapShot Multiplex Ready Mix, 1 μl primers and 4 μl DNA templates that were purified with the QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany). The PCR cycling program was as follows: an initial cycle at 95°C/2 min; 25 cycles of 94°C/30 s, 57°C/30 s and 72°C/40 s; and a final cycle at 4°C until analysis. The extension products were then purified with 1 U of shrimp alkaline phosphatase (SAP) and exonuclease I at 37°C for 15 min followed by a 15 min incubation at 80°C to inactivate the enzyme. After purification with SAP, the extension products were analyzed with the ABI 3730xl DNA Analyzer and GeneMapper 4.1 (Applied Biosystems, Carlsbad, CA, USA). At last, 5% of the random duplicate samples from each genotyping were selected for quality control.

3D structure modeling and GRK5 docking study

The crystal structures of the GRK5 (PDB ID: 4WNK, Homan KT et al., 2015) were established using the Insight II/Builder program [39]. The structure of SNP-encoding GRK5 proteins was predicted based on the native conformation to determine how the Gln41Leu or Arg304His amino acid changes encoded by the SNPs altered protein structure. The analysis was visualized using SWISSPDB viewer. The root mean square deviation values were calculated to correct for the structural deviation between the native and mutant GRK5 proteins. The structural integrity of the models was visually examined with Discovery Studio (DS) Visualizer 3.1 (http://accelrys.com/products/discoverystudio/ visualization-download.php), which was also used to generate images of the structures.

Plasmid construction and transfection

The DNA fragment encoding the GRK5 precursor was ligated to the pre-cut GV230 vector, and an enhanced green fluorescent protein (eGFP) tag was added to the GRK5 C-terminal. Two GRK5 mutant plasmids (rs2230345 and rs2230349) and a wild-type (wt) GRK5 plasmid were constructed. The polymorphism at rs2230345 was amplified with the primers 5’-ACATTAGCCTGTGCAGGGATGGATCAGTCTGCCTTTT-3’ and 5’-GTCGAGCGTCGACCTTCCTCCGAAGGACCATAG-3’.
TTCACACAGGCTAATGTGAGGGAACCTTCAG-3’.

For rs2230349, the polymorphism was amplified with the primers 5’-ACCTCCACCATGAGAAACCCGTACC GAGATC-3’ and 5’-GGTTTCTCTATGGTTAGGAGTC TTCTAAGGCCGAG-3’. Site-directed mutagenesis was performed to modify single bases. In the rs2230345 plasmid, the base 188 (A) was mutated to T and in the rs2230349 plasmid, the base 975 (G) was mutated to A. The PCR products from these three plasmids were the same size, and their sequences were exactly the same except for the mutation site. All of the plasmid constructs were generated and authenticated by Genechem Inc. (Shanghai, China). Before transfection, SH-SY5Y cells were seeded in six-well plates at approximately 70% confluence in complete medium (DMEM supplemented with 10% FBS) without antibiotics. Opti-medium (100 μl) mixed with 1 μg plasmid DNA and 1 μl DNA-IN SY5Y transfection reagents (GlobalStem, USA) constituted the transfection complex, and a volume of 62.5 μl were added to each well before incubation at 37°C in 5% CO2 for 6 h. After incubation, plasmid enriched medium was replaced with routine medium and the cells were cultured for 24-48 h under the same condition. The expression of green fluorescence was observed with a fluorescence microscope (Leica DMI300B, Germany) and was used to calculate the transfection efficiency.

**Cell culture and Aβ42 administration**

SH-SY5Y cells purchased from Genechem Inc. (Shanghai, China) were cultured in complete Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin antibiotics at 37°C in 5% CO2. Confluent cell cultures were passaged with 0.25% trypsin containing EDTA as previously described [40]. For the best results, continuous passages for at least two generations were recommended to restore cell activity after thawing. A liquor stock solution of Aβ42 was prepared by gently mixing 113 μl Aβ42 solutions (2 mg/ml) and 887 μl PBS (1 mM). The dilute solutions of Aβ42 (50 μM) were incubated in a water bath for 30 min at 37°C to activate monomers and form the Aβ42 aggregates. In our study, final concentrations of 5 μM and 1 μM Aβ42 aggregates were used to form the concentration gradient, and Aβ42-treated cells were cultured at 37°C in 5% CO2 for 24 h before subsequent experiments.

**Western blotting analysis**

Transfected cells or non-transfected cells at 90% confluence were harvested and lysed in RIPA buffer (Solarbio, Beijing, China) complemented with 2% protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany), 1% PMSF (Solarbio, Beijing, China) and 1% NaF (Solarbio, Beijing, China). In addition to total protein extraction, membrane proteins and cytosolic proteins were extracted using the Membrane Protein Extraction Kit (Thermo Fisher, USA), and the procedures were performed in accordance with the manufacturer’s protocols. Three types of transfected cells were used to detect membrane and cytosolic proteins in cells robustly expressing wild-type GRK5, rs2230345 or rs2230349. For the mice, the hippocampus on both sides was detached from the deep cortical layer and homogenized with RIPA complexes and cell lysis solution. The following steps were performed similarly regardless of the source of the protein (cells or tissues) as previously described [41]. The only differences were the antibody used and their dilution ratios, which included phosphorylated tau, or p-tau, (Abcam; 1:1000), tau (Cell Signaling; 1000), GRK5 (Abcam; 1:600) and beta-actin (Solarbio; 1:1000).

**Patient samples**

Samples from 292 AD patients and 300 matched individuals were obtained from the Shenzhen Nanshan Center for Disease Control and Prevention between April 2008 and February 2013. The clinical diagnosis of AD was based upon the revised criteria of the National Institute of Aging and Alzheimer’s Association (NIA-AA). The Mini-Mental Status Examination (MMSE) was used to score cognitive impairment as previously described [40]. The AD group samples were confirmed to come from patients who did not have other types or compound types of dementia. The control group samples were confirmed to come from patients who were free of nervous system diseases and a variety of acute illnesses, including hyperpyrexia and acute coronary syndrome. Samples from patients in the active stages of other diseases were excluded from both groups. All experiments on human subjects were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all the enrolled participants, and this study was approved by the Ethics Committee of the Affiliated Hospital of Guangdong Medical University.

**Statistical analyses**

The data were presented as the means ± SEM, and variance analysis was performed using SPSS 19.0. Genotype and allele frequencies were quantified. The Hardy–Weinberg equilibrium was estimated between the expected and actual genotype distributions using Chi-squared test. The student’s t-test was used for genotypic distributions and enumeration data (allele and genotype distributions), which were compared using Chi-squared test or Fisher’s exact. In the sub-categories of age and ApoEε4 carrier, analyses were repeated as above. The odds ratios (OR) represented the strength of the correlation, and the 95% confidence interval (CI) was used to evaluate prevalence risks. Haplotype analysis was performed using Haploview 4.2. In all comparisons, P values were calculated and corrected for the assessment of statistical significance; P<0.05 was considered statistically significant.
Abbreviations

Aβ, β-amyloid
AD, Alzheimer’s disease
ApoE, apolipoprotein E
APP, amyloid precursor
EOAD, Early Onset Alzheimer Disease
ELISA, enzyme-linked immunosorbent assay
ESC, embryonic stem cell
FBS, fetal bovine serum
GPCRs, G protein-coupled receptors
GRK5, G protein-coupled receptor kinase-5
LOAD, Late Onset Alzheimer Disease
PCR, polymerase chain reaction
PSEN1, presenilin 1
PSEN2, presenilin 2
SNPs, single-nucleotide polymorphisms
SPF, specific pathogen free

Author contributions

Conceived and designed the experiments: LLC BZ.
Performed the experiments: YZ JHZ MKY YJC SYL YW
XLZ HC TC PRH HM ZL HT. Analyzed the data: LLC
YZ JHZ MKY. Contributed reagents/materials/analysis
tools: LLC BZ. Wrote the paper: LLC YZ.

ACKNOWLEDGMENTS AND FUNDING

This work was supported by funding from the
National Nature Science Foundation of China (81671181,
81401061, 81271214 and 81301038) and the Open Project
Program or Guangdong Key laboratory of age-related
cardiac and cerebral diseases (4CX16008G).

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Bras J, Djaldetti R, Alves AM, Mead S, Darwent L, Lleo A,
Molinuevo JL, Blesa R, Singleton A, Hardy J, Clarimon J,
Guerreiro R. Exome sequencing in a consanguineous family
clinically diagnosed with early-onset Alzheimer’s disease
identifies a homozygous CTSF mutation. Neurobiol Aging.
2016;46:236 e231-236.
2. Nikolakopoulos AM, Georgakopoulos A, Robakis NK.
Presenilin 1 promotes trypsin-induced neuroprotection via
the par2/erk signaling pathway. Effects of presenilin 1 fad
mutations. Neurobiol Aging. 2016;42:41-49.
3. Luo X, Qiu T, Jia Y, Huang P, Xu X, Yu X, Shen Z, Jiaerk
Y, Guan X, Zhou J, Zhang M, ADNI. Intrinsin functional
connectivity alterations in cognitively intact elderly apoe
epsilon0 carriers measured by eigenvector centrality
mapping are related to cognition and CSF biomarkers: A
preliminary study. Brain Imaging Behav. 2016. [Epub ahead
of print].
4. Fitz NF, Tapias V, Cronican AA, Castranio EL, Saleem
M, Carter AY, Lefterova M, Lefterov I, Koldamova R.
Opposing effects of Apoe/Apoa1 double deletion on
amyloid-beta pathology and cognitive performance in APP
mice. Brain. 2015;138:3699-3715.
5. Liu J, Rasul I, Sun Y, Wu G, Li L, Premont RT, Suo WZ.
Grk5 deficiency leads to reduced hippocampal acetylcholine
level via impaired presynaptic m2/m4 autoreceptor
desensitization. J Biol Chem. 2009;284:19564-19571.
6. He M, Singh P, Cheng S, Zhang Q, Peng W, Ding X, Li L,
Liu J, Premont RT, Morgan D, Burns JM, Swerdlov RH,
Suo WZ. Grk5 deficiency leads to selective basal forebrain
cholinergic neuronal vulnerability. Sci Rep. 2016;6:26116.
7. Lessel D, Muhammad T, Casar Tena T, Moepps B,
Burkhalter MD, Hitz MP, Toka O, Rentzsch A, Schubert S,
Schalinski A, Bauer UM, Kubisch C, Ware SM, et al. The
analysis of heterotaxy patients reveals new loss-of-function
variants of GRK5. Sci Rep. 2016;6:33231.
8. Singh P, Peng W, Zhang Q, Ding X, Suo WZ. Grk5
deficiency leads to susceptibility to intermittent hypoxia-
induced cognitive impairment. Behav Brain Res.
2016;302:29-34.
9. Cheng S, Li L, He S, Liu J, Sun Y, He M, Grasing K,
Premont RT, Suo WZ. Grk5 deficiency accelerates [beta]-
amyloid accumulation in tg2576 mice via impaired
cholinergic activity. J Biol Chem. 2010;285:41541-41548.
10. Kang S, Hong X, Ruan CW, Yu P, Yu SS, Chen M,
Zhang DF, Fan HM, Liu ZM. Effects of GRK5 and adrb1
polymorphisms influence on systolic heart failure. J Transl
Med. 2015;13:44.
11. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich
SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh
RR, Spertus JA, Koch WJ, Kardia SL, et al. A GRK5
polymorphism that inhibits beta-adrenergic receptor
signaling is protective in heart failure. Nat Med.
2008;14:510-517.
12. Lobmeyer MT, Wang L, Zineh I, Turner ST, Gums JG,
Chapman AB, Cooper-DeHoff RM, Beitzelshees AL,
Bailey KR, Boerwinkle E, Pepine CJ, Johnson JA.
Polymorphisms in genes coding for GRK2 and GRK5 and
response differences in antihypertensive-treated patients.
Pharmacogen Genom. 2011;21:42-49.
13. Baanefur M, Morgan DH, Yao H, Tran TM, Hammitt RA,
Sabui S, McMurray JS, Lichtarge O, Clark RB. Role for
the regulator of G-protein signaling homology domain
of G protein-coupled receptor kinases 5 and 6 in beta
2-adrenergic receptor and rhodopsin phosphorylation.
Molec Pharmacol. 2010;77:405-415.
14. Philipp M, Berger IM, Just S, Caron MG. Overlapping and
opposing functions of G protein-coupled receptor kinase 2
(GRK2) and GRK5 during heart development. J Biol Chem.
2014;289:26119-26130.
15. Bojic T, Sudar E, Mikhailidis D, Alavantic D, Isenovic E. The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology. Arch Med Sci. 2012;8:970-977.

16. Monto F, Oliver E, Vicente D, Buendia F, Rueda J, Aguero J, Almenar J, Valdèncabres C, Rovira E, Muedra V, Noguera MA, Ivorra MD, D’Ocon P. Beta2- and beta1-adrenoceptor expression exhibits a common regulatory pattern with GRK2 and GRK5 in human and animal models of cardiovascular diseases. J Cardiovasc Pharmacol. 2015;66:478-486.

17. Traynham CJ, Cannavo A, Zhou Y, Vouga AG, Woodall BP, Hallmann J, Ibetti J, Gold JI, Chuprun JK, Gao E, Koch WJ. Differential role of G protein-coupled receptor kinase 5 in physiological versus pathological cardiac hypertrophy. Circ Res. 2015;117:1001-1012.

18. Xu H, Jiang X, Shen K, Fischer CC, Wedegaertner PB. The regulator of G protein signaling (rgs) domain of G protein-coupled receptor kinase 5 (GRK5) regulates plasma membrane localization and function. Molec Biol Cell. 2014;25:2105-2115.

19. Suo WZ, Li L. Dysfunction of G protein-coupled receptor kinases in Alzheimer’s disease. Sci World J. 2010;10:1667-1678.

20. Lara A, Damasceno DD, Pires R, Gros R, Gomes ER, Gavioli M, Lima RF, Guimaraes D, Lima P, Bueno CR Jr, Vasconcelos A, Roman-Campos D, Menezes CA, et al. Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure. Mol Cell Biol. 2010;30:1746-1756.

21. Fgaier H, Mustafa IH, Awad AA, Elkamel A. Modeling the interaction between β-amyloid aggregates and choline acetyltransferase activity and its relation with cholinergic dysfunction through two-enzyme/two-compartment model. Comput Math Methods Med. 2015;2015:923762.

22. Parikh V, Bernard CS, Naughton SX, Yegla B. Interactions between αβ oligomers and presynaptic cholinergic signaling: Age-dependent effects on attentional capacities. Behav Brain Res. 2014;274:30-42.

23. Zhang Y, Chen L, Shen G, Zhao Q, Shangguan L, He M. Grk5 dysfunction accelerates tau hyperphosphorylation in App (swe) mice through impaired cholinergic activity. Neuroreport. 2014;25:542-547.

24. Takahashi M, Uchikado H, Caprotti D, Weidenheim KM, Dickson DW, Ksiezek-Reding H, Pasinetti GM. Identification of G-protein coupled receptor kinase 2 in paired helical filaments and neurofibrillary tangles. J Neuropathol Exp Neurol. 2006;65:1157-1169.

25. Ding B, Gluhkova A, Sobczyk-Kojiro K, Mosberg HI, Tesmer JJ, Chen Z. Unveiling the membrane-binding properties of N-terminal and C-terminal regions of G protein-coupled receptor kinase 5 by combined optical spectroscopies. Langmuir. 2014;30:823-831.

26. Dorn GW 2nd, Liggett SB. Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure. Molec Pharmacol. 2009;76:466-480.

27. Yang P, Gluhkova A, Tesmer JJ, Chen Z. Membrane orientation and binding determinants of G protein-coupled receptor kinase 5 as assessed by combined vibrational spectroscopic studies. PloS One. 2013;8:e82072.

28. Komolov KE, Bhadrwaj A, Benovic JLM. Atomic structure of GRK5 reveals distinct structural features novel for G protein-coupled receptor kinases. J Biol Chem. 2015;290:20629-20647.

29. Singh P, Wang B, Maeda T, Palczewski K, Tesmer JJ. Structures of rhodopsin kinase in different ligand states reveal key elements involved in G protein-coupled receptor kinase activation. J Biol Chem. 2008;283:14053-14062.

30. Huang CC, Orban T, Jastrzebska B, Palczewski K, Tesmer JJ. Activation of G protein-coupled receptor kinase 1 involves interactions between its N-terminal region and its kinase domain. Biochemistry. 2011;50:1940-1949.

31. Homan KT, Larimore KM, Elkins JM, Szklarz M, Knapp S, Tesmer JJ. Identification and structure-function analysis of subfamily selective G protein-coupled receptor kinase inhibitors. ACS Chem Biol. 2015;10:310-319.

32. Gold JI, Martini JS, Hallmann J, Gao E, Chuprun JK, Lee L, Tilley DG, Rabinowitz JE, Bossuyt J, Bers DM, Koch WJ. Nuclear translocation of cardiac G protein-coupled receptor kinase 5 downstream of select Gq-activating hypertrophic ligands is a calmodulin-dependent process. PloS One. 2013;8:e57324.

33. Krupnick JG, Benovic JLM. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol. 1998;38:289-319.

34. Inagaki S, Ghirlando R, Vishnivetskiy SA, Homan KT, White JF, Tesmer JJ, Gurevich VV, Grisshammer R. G protein-coupled receptor kinase 2 (GRK2) and 5 (GRK5) exhibit selective phosphorylation of the neurotensin receptor in vitro. Biochemistry. 2015;54:4320-4329.

35. Wu JH, Zhang L, Fanaroff AC, Cai X, Sharma KC, Brian L, Exum ST, Shenoy SK, Peppel K, Freedman NJ. G protein-coupled receptor kinase-5 attenuates atherosclerosis by regulating receptor tyrosine kinases and 7-transmembrane receptors. ArteriosclerThromb Vasc Biol. 2012;32:308-316.

36. Suo Z, Wu M, Citron BA, Wong GT, Festoff BW. Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer’s disease: An association with early beta-amyloid accumulation. J Neurosci. 2004;24:3444-3452.

37. Baker-Nigh A, Vahedi S, Davis EG, Weintraub S, Bigio EH, Klein WL, Geula C. Neuronal amyloid-beta accumulation
within cholinergic basal forebrain in ageing and Alzheimer’s disease. Brain. 2015;138:1722-1737.

38. Sun W, Lee S, Huang X, Liu S, Inayathullah M, Kim KM, Tang H, Ashford JW, Rajadas J. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer’s disease treatment. Sci Rep. 2016;6:34784.

39. Homan KT, Waldschmidt HV, Glukhova A, Cannavo A, Song J, Cheung JY, Koch WJ, Larsen SD, Tesmer JJ. Crystal structure of G protein-coupled receptor kinase 5 in complex with a rationally designed inhibitor. J Biol Chem. 2015;290:20649-20659.

40. Cui L, Li Y, Ma G, Wang Y, Cai Y, Liu S, Chen Y, Li J, Xie Y, Liu G, Zhao B, Li K. A functional polymorphism in the promoter region of microRNA-146a is associated with the risk of Alzheimer disease and the rate of cognitive decline in patients. PloS One. 2014;9:e89019.

41. Cui L, Cai Y, Cheng W, Liu G, Zhao J, Cao H, Tao H, Wang Y, Yin M, Liu T, Liu Y, Huang P, Liu Z, et al. A novel, multi-target natural drug candidate, matrine, improves cognitive deficits in Alzheimer’s disease transgenic mice by inhibiting αβ aggregation and blocking the RAGE/αβ axis. Mol Neurobiol. 2017;54:1939-1952.